| Not Yet Recruiting | A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untre NCT07459543 | Bristol-Myers Squibb | Phase 4 |
| Not Yet Recruiting | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab NCT07504796 | NYU Langone Health | Phase 4 |
| Not Yet Recruiting | IL-17 Blockade to Decrease irAEs (REPLAY) NCT07237594 | Duke University | Phase 1 |
| Recruiting | Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis NCT07281924 | University of Wisconsin, Madison | Phase 1 / Phase 2 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 NCT06887348 | Replimune, Inc. | — |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma NCT07288203 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Recruiting | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing NCT06066138 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis NCT04129515 | Brown University | Phase 1 / Phase 2 |
| Withdrawn | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the NCT05717140 | Mayo Clinic | Phase 1 |
| Recruiting | Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100 | Kevin Kim, MD | Phase 2 |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma NCT07086105 | Adze Biotechnology Australia Pty Ltd | Phase 1 |
| Recruiting | Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma NCT07112170 | University Health Network, Toronto | N/A |
| Active Not Recruiting | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Trea NCT06961786 | TILT Biotherapeutics Ltd. | Phase 1 |
| Terminated | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors NCT06799533 | Pfizer | Phase 1 |
| Recruiting | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive L NCT06940739 | Iovance Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | In Vivo Liquid Biopsy of Melanoma (Cytophone) NCT06488365 | Cytoastra | N/A |
| Not Yet Recruiting | Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma NCT06710093 | Royal Marsden NHS Foundation Trust | — |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Recruiting | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progre NCT05629546 | Washington University School of Medicine | Phase 1 |
| Recruiting | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable NCT05896839 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma NCT06424626 | Peking University Cancer Hospital & Institute | Phase 1 |
| Unknown | Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma NCT03803397 | PrimeVax Immuno-Oncology Inc. | Phase 1 |
| Completed | IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melan NCT07436390 | Institute of Oncology Ljubljana | N/A |
| Recruiting | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Ne NCT05913388 | Providence Health & Services | Phase 2 |
| Active Not Recruiting | eFLASH for Skin Lesions of Malignant Melanomas NCT06549439 | University of Zurich | N/A |
| Unknown | Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet NCT06236360 | University Hospital Rijeka | N/A |
| Unknown | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment NCT06151847 | University of Kansas Medical Center | Phase 2 |
| Completed | CALM: Managing Distress in Malignant Brain Cancer NCT06180460 | Virginia Commonwealth University | N/A |
| Recruiting | Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613 | Obsidian Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Cryoablation+Ipilimumab+Nivolumab in Melanoma NCT05779423 | Massachusetts General Hospital | Phase 2 |
| Completed | Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma NCT05304546 | Dr. Ronnie Shapira | Phase 2 |
| Recruiting | Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis NCT05856565 | Nantes University Hospital | — |
| Completed | A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings NCT05954546 | Pfizer | — |
| Withdrawn | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer P NCT04987996 | Providence Health & Services | Phase 2 |
| Completed | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases NCT05704933 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Recruiting | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced NCT05655312 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Suspended | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 In NCT05764395 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1 NCT06586580 | Centre Hospitalier Universitaire de Besancon | — |
| Recruiting | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants W NCT05727904 | Iovance Biotherapeutics, Inc. | Phase 3 |
| Recruiting | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Met NCT05588453 | Kari Kendra | Phase 1 / Phase 2 |
| Terminated | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Th NCT05695898 | University of California, San Francisco | Phase 1 |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Completed | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1 NCT05578872 | Anaveon AG | Phase 1 / Phase 2 |
| Recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma NCT05641012 | Institut Jean-Godinot | — |
| Active Not Recruiting | A Study of LN-144 in People With Metastatic Melanoma to the Brain NCT05640193 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma NCT05628883 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or D NCT05607095 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic NCT05388877 | Mayo Clinic | Phase 1 |
| Terminated | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa- NCT05393713 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Bra NCT05341349 | Emory University | Phase 1 |
| Recruiting | Biomarkers in Immunotherapy of Melanoma NCT05878977 | Institute of Oncology Ljubljana | N/A |
| Active Not Recruiting | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazol NCT05470283 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations NCT05810740 | Pierre Fabre Medicament | Phase 1 |
| Recruiting | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma NCT05155033 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) NCT05169957 | University of Michigan Rogel Cancer Center | Phase 1 |
| Completed | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects NCT06469138 | BerGenBio ASA | Phase 1 |
| Recruiting | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresecta NCT05361174 | Iovance Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT04941365 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Recruiting | Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma NCT04903119 | Rina Plattner | Phase 1 |
| Active Not Recruiting | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D1 NCT05155254 | IO Biotech | Phase 3 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia NCT07422779 | Institute of Oncology Ljubljana | N/A |
| Completed | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts NCT04960059 | The Christie NHS Foundation Trust | — |
| Terminated | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma NCT04955743 | Yale University | Phase 2 |
| Active Not Recruiting | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma NCT05034536 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma NCT04930783 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases NCT05026983 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma NCT04697576 | Carlo Contreras | Phase 1 |
| Terminated | Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib an NCT05848219 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma NCT04967196 | Mayo Clinic | Phase 1 |
| Unknown | Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations NCT05103891 | Pierre Fabre Medicament | Phase 1 |
| Active Not Recruiting | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) NCT04557956 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Terminated | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets NCT04899921 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | 7T MRI Scan for the Early Detection of Melanoma Brain Metastases NCT04941430 | University of Southern California | N/A |
| Completed | Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patien NCT06369428 | Novartis | — |
| Withdrawn | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) NCT04060407 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 / Phase 2 |
| Recruiting | Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Bioma NCT07407166 | Institute of Oncology Ljubljana | N/A |
| Recruiting | Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma NCT03743298 | Aivita Biomedical, Inc. | Phase 1 |
| Withdrawn | Sargramostim (GM-CSF) + PD-1 NCT04703426 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases NCT03698162 | University of Southern California | N/A |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Withdrawn | Surgery of Melanoma Metastases After Systemic Therapy NCT04242329 | Vastra Gotaland Region | Phase 2 |
| Terminated | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma NCT04698187 | Regeneron Pharmaceuticals | Phase 2 |
| Recruiting | Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases NCT04793737 | Karolinska University Hospital | N/A |
| Unknown | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation NCT04633902 | California Pacific Medical Center Research Institute | Phase 2 |
| Completed | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases NCT04698161 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | — |
| Terminated | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma NCT04695977 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Completed | A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma NCT04911998 | Pierre Fabre Medicament | — |
| Withdrawn | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma NCT04759846 | Pierre Fabre Medicament | Phase 1 |
| Recruiting | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Sol NCT04771520 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab i NCT04511013 | SWOG Cancer Research Network | Phase 2 |
| Terminated | A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Ad NCT04625205 | BioNTech US Inc. | Phase 1 |
| Recruiting | Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy NCT03888950 | Centre Hospitalier Universitaire de Nice | N/A |
| Terminated | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Soli NCT03991741 | Gregory Daniels | Phase 1 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Recruiting | PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy NCT04272658 | University Hospital, Brest | — |
| Active Not Recruiting | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With M NCT04645680 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Tr NCT05611229 | Novartis Pharmaceuticals | — |
| Completed | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma NCT04109456 | InxMed (Shanghai) Co., Ltd. | Phase 1 |
| Completed | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma NCT04217473 | TILT Biotherapeutics Ltd. | Phase 1 |
| Withdrawn | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneo NCT03773744 | Turnstone Biologics, Corp. | Phase 1 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Withdrawn | SBRT as a Vaccination for Metastatic Melanoma NCT04042506 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumo NCT04140500 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Active Not Recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M NCT03816332 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanom NCT04021420 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma NCT03225365 | Hospices Civils de Lyon | N/A |
| Withdrawn | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients NCT04955262 | Nektar Therapeutics | Phase 1 |
| Completed | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Bra NCT03898908 | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
| Completed | A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Partici NCT03875079 | Hoffmann-La Roche | Phase 1 |
| Terminated | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212 | Mayo Clinic | Phase 1 |
| Terminated | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma NCT04337931 | Apexigen America, Inc. | Phase 2 |
| Completed | Radiation and Combination Immunotherapy for Melanoma NCT03850691 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade NCT03474497 | Megan Daly, MD | Phase 1 / Phase 2 |
| Recruiting | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors NCT03645928 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Unknown | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation NCT03925350 | California Pacific Medical Center Research Institute | Phase 2 |
| Completed | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain NCT03873818 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention NCT03817125 | Parker Institute for Cancer Immunotherapy | Phase 1 |
| Terminated | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression NCT03724968 | Elizabeth Davis | Phase 2 |
| Completed | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) NCT03679767 | Incyte Corporation | Phase 2 |
| Unknown | Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous Sy NCT05510466 | University Hospital, Montpellier | — |
| Completed | A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma Wit NCT03625141 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma NCT03646617 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Terminated | Safety of ADU-1604 in Adults With Metastatic Melanoma NCT03674502 | Aduro Biotech, Inc. | Phase 1 |
| Completed | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With A NCT03708328 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melan NCT03597282 | BioNTech US Inc. | Phase 1 |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Completed | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma NCT01904123 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or NCT03425461 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Mel NCT03445533 | Idera Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease NCT03025256 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma NCT03728465 | University Hospital Tuebingen | Phase 2 |
| Terminated | A Study of ADXS-NEO Expressing Personalized Tumor Antigens NCT03265080 | Advaxis, Inc. | Phase 1 |
| Withdrawn | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients NCT03126461 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma NCT03047928 | Inge Marie Svane | Phase 1 / Phase 2 |
| Completed | TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) NCT03475134 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Terminated | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes NCT03526185 | Yale University | EARLY_Phase 1 |
| Completed | A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Mon NCT03430297 | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 |
| Withdrawn | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma NCT03297463 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | A Study of ASN007 in Patients With Advanced Solid Tumors NCT03415126 | Asana BioSciences | Phase 1 |
| Completed | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRA NCT03864042 | Pfizer | Phase 1 |
| Completed | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma NCT03276832 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma NCT03149029 | Massachusetts General Hospital | Phase 2 |
| Completed | Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors NCT03326973 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Active Not Recruiting | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metas NCT03131908 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab NCT03123783 | Apexigen America, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Me NCT03175432 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old NCT03155217 | University Hospital, Montpellier | — |
| Active Not Recruiting | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy NCT03122522 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02748564 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers NCT03073473 | Cota Inc. | — |
| Completed | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Mel NCT02816021 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery NCT03021460 | Mayo Clinic | Phase 1 |
| Terminated | Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomark NCT02740920 | Canadian Cancer Trials Group | Phase 2 |
| Unknown | Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Me NCT03013101 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Active Not Recruiting | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutate NCT02910700 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study NCT02631447 | Fondazione Melanoma Onlus | Phase 2 |
| Completed | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 | Emory University | Phase 1 |
| Completed | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Meta NCT02857270 | Eli Lilly and Company | Phase 1 |
| Active Not Recruiting | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Co NCT02713269 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma NCT02581930 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Immune Monitoring in Metastatic Melanoma NCT04158544 | University of Regensburg | — |
| Completed | RATIO: Rational Approach To Immuno-Oncology NCT02700971 | AHS Cancer Control Alberta | N/A |
| Completed | Imaging FDG Flare in Melanoma NCT02791594 | Abramson Cancer Center at Penn Medicine | — |
| Completed | A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonu NCT02768207 | Hoffmann-La Roche | Phase 2 |
| Completed | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication NCT02595866 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas NCT02375984 | Saint John's Cancer Institute | Phase 2 |
| Completed | Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study NCT02038348 | Assistance Publique Hopitaux De Marseille | Phase 2 |
| Completed | Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendrit NCT02678741 | Elios Therapeutics, LLC | Phase 1 / Phase 2 |
| Completed | Molecular Characterization of Advanced Stage Melanoma by Blood Sampling NCT02862743 | CHU de Reims | N/A |
| Unknown | Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients NCT02625337 | The Netherlands Cancer Institute | Phase 2 |
| Completed | A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic NCT02644967 | Idera Pharmaceuticals, Inc. | Phase 2 |
| Unknown | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients NCT02608437 | Italian Network for Tumor Biotherapy Foundation | Phase 1 |
| Completed | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Met NCT02360579 | Iovance Biotherapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafe NCT02224781 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Mel NCT02521870 | Dynavax Technologies Corporation | Phase 1 / Phase 2 |
| Completed | Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Tre NCT02500576 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib NCT02357732 | University of Pittsburgh | Phase 1 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma NCT02489266 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types NCT06075524 | Mayo Clinic | — |
| Completed | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Stu NCT02424916 | Nantes University Hospital | Phase 1 / Phase 2 |
| Completed | Radiotherapy & Combi in Metastatic Melanoma NCT02392871 | Melanoma and Skin Cancer Trials Limited | Phase 1 / Phase 2 |
| Completed | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies NCT02626065 | Hospices Civils de Lyon | Phase 4 |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms NCT02150369 | Duke University | — |
| Completed | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stag NCT01740557 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metasta NCT02027935 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma NCT02306850 | St. Louis University | Phase 2 |
| Completed | Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes NCT02310451 | Centre Hospitalier Universitaire de Nice | N/A |
| Terminated | Vemurafenib Plus Cobimetinib in Metastatic Melanoma NCT02414750 | Netherlands Working Group on Immunotherapy of Oncology | Phase 2 |
| Completed | Vemurafenib and TIL Therapy for Metastatic Melanoma NCT02354690 | Inge Marie Svane | Phase 1 / Phase 2 |
| Completed | Peginterferon and TIL Therapy for Metastatic Melanoma NCT02379195 | Inge Marie Svane | Phase 1 / Phase 2 |
| Completed | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors NCT03176485 | University of Arizona | N/A |
| Active Not Recruiting | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma NCT01955460 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma NCT02278887 | The Netherlands Cancer Institute | Phase 3 |
| Completed | A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or M NCT02177110 | Cancer Trials Ireland | — |
| Withdrawn | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases NCT02065466 | University of Arizona | Phase 1 / Phase 2 |
| Completed | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma NCT02073123 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Terminated | Immunotherapy Study for Patients With Stage IV Melanoma NCT02054520 | NewLink Genetics Corporation | Phase 2 |
| Terminated | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are NCT02097225 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma NCT01876212 | Walter J. Storkus | Phase 2 |
| Completed | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma NCT02117362 | Providence Health & Services | Phase 1 |
| Completed | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists NCT02126579 | Craig L Slingluff, Jr | Phase 1 / Phase 2 |
| Completed | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melan NCT02141542 | F. Stephen Hodi, MD | Phase 1 |
| Terminated | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery NCT02097732 | University of Michigan Rogel Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mut NCT01989585 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma NCT02142335 | California Cancer Assocaties for Research & Excellence | Phase 2 |
| Withdrawn | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma NCT01689870 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Terminated | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment NCT01995344 | The Christie NHS Foundation Trust | Phase 2 |
| Terminated | Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Me NCT01838200 | Ludwig Institute for Cancer Research | Phase 1 |
| Unknown | Multicenter Tissue Registry in Melanoma NCT05750511 | Dermatologic Cooperative Oncology Group | — |
| Terminated | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma NCT02062359 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipilimumab-induced Lung Toxicity: Observational Study NCT02755233 | University of Zurich | — |
| Withdrawn | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Ch NCT01933061 | Celgene Corporation | Phase 2 |
| Completed | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma NCT01993719 | National Cancer Institute (NCI) | Phase 2 |
| Completed | The Jules Bordet Institute Molecular Profiling Program Feasibility Trial NCT01932489 | Jules Bordet Institute | N/A |
| Completed | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma NCT02158520 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer NCT01902173 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib NCT01876641 | Mohammed M Milhem | Phase 1 |
| Withdrawn | Open-Label Study of TPI 287 for Patients With Metastatic Melanoma NCT01340729 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is NCT01940809 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously NCT01927419 | Bristol-Myers Squibb | Phase 2 |
| Completed | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma NCT01807182 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanom NCT01495988 | Melanoma Research Foundation Breakthrough Consortium | Phase 2 |
| Unknown | Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment NCT01920516 | International Group of Endovascular Oncology | — |
| Completed | Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques NCT01558349 | Centre Hospitalier Universitaire de Nīmes | — |
| Terminated | A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma NCT01864538 | ImmunoGenesis | Phase 2 |
| Terminated | HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma NCT01856023 | Clinigen, Inc. | Phase 4 |
| Completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer NCT01738139 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma NCT01689974 | NYU Langone Health | Phase 2 |
| Completed | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts NCT01701674 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Withdrawn | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma NCT01833767 | Western Regional Medical Center | Phase 2 |
| Completed | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Mela NCT01621490 | Bristol-Myers Squibb | Phase 1 |
| Withdrawn | Study of Immune Responses in Patients With Metastatic Melanoma NCT01416844 | Providence Health & Services | Phase 2 |
| Completed | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma NCT01659151 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases NCT01644591 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma NCT01683188 | Clinigen, Inc. | Phase 4 |
| Withdrawn | Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls NCT01312506 | University of Pittsburgh | — |
| Active Not Recruiting | Aerosolized Aldesleukin in Treating Patients With Lung Metastases NCT01590069 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Peptide Vaccinations Plus GM-CT-01 in Melanoma NCT01723813 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 1 / Phase 2 |
| Completed | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Me NCT02009397 | University of Louisville | Phase 1 / Phase 2 |
| Terminated | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox NCT02009384 | University of Louisville | Phase 2 |
| Unknown | Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors NCT01878396 | Istituto Oncologico Veneto IRCCS | — |
| Terminated | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells NCT01495572 | National Cancer Institute (NCI) | Phase 2 |
| Completed | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB NCT01497808 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Terminated | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Met NCT01457131 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Part NCT01425008 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma NCT01468818 | National Cancer Institute (NCI) | Phase 2 |
| Completed | PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy NCT01415167 | Prometheus Laboratories | — |
| Active Not Recruiting | Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. NCT01416831 | Providence Health & Services | Phase 2 |
| Terminated | Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma NCT01369875 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies NCT01364051 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic NCT01335009 | Eisai Inc. | Phase 2 |
| Terminated | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma NCT01369888 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphoc NCT01319565 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Rem NCT01258855 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain NCT01280565 | AB Science | Phase 3 |
| Active Not Recruiting | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot B NCT01134614 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma NCT01212276 | Morphotek | Phase 1 |
| Completed | Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma NCT01743157 | California Pacific Medical Center Research Institute | Phase 1 / Phase 2 |
| Terminated | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes NCT01273181 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer NCT01218867 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 NCT01216696 | National Center for Tumor Diseases, Heidelberg | Phase 2 |
| Terminated | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes NCT01236573 | National Institutes of Health Clinical Center (CC) | Phase 1 / Phase 2 |
| Terminated | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma NCT01191034 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 1 / Phase 2 |
| Terminated | Metronomic Therapy in Patients With Metastatic Melanoma NCT01542255 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Unknown | Of 18F MEL050 Using PET/CT in Metastatic Melanoma NCT01620749 | Cooperative Research Centre for Biomedical Imaging Development | EARLY_Phase 1 |
| Terminated | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic M NCT01160445 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipilimumab + Temozolomide in Metastatic Melanoma NCT01119508 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti NCT01118091 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma NCT01014351 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma NCT01029873 | Altor BioScience | Phase 1 / Phase 2 |
| Terminated | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injection NCT01082887 | Nantes University Hospital | Phase 1 / Phase 2 |
| Terminated | Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melan NCT01216436 | Duke University | Phase 1 |
| Terminated | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat NCT00925132 | University of Iowa | Phase 1 / Phase 2 |
| Completed | Dose Escalation Study of MLN4924 in Adults With Melanoma NCT01011530 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma NCT00747825 | Molecular Insight Pharmaceuticals, Inc. | Phase 1 |
| Completed | Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma NCT01005745 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Study of Gene Modified Immune Cells in Patients With Advanced Melanoma NCT00910650 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Unknown | A Study to Assess PV-10 Chemoablation of Cancer of the Liver NCT00986661 | Provectus Biopharmaceuticals, Inc. | Phase 1 |
| Completed | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma NCT00984464 | Oncolytics Biotech | Phase 2 |
| Completed | A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma NCT00804908 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma NCT00734188 | Pain Therapeutics | Phase 1 |
| Completed | Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma NCT00881049 | Peking University | Phase 2 |
| Completed | Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma NCT01005472 | Jonsson Comprehensive Cancer Center | Phase 1 |